Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX208 in Refractory Primary Brain Tumors
NCT05092802Phase 2Unknown
- Sponsor
- Henlius
- Start
- Dec 2021
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HLX208 in primary brain tumor, sponsored by Henlius. Status: unknown.
02
Drugs
HLX208
03
Conditions
primary brain tumor
Beyond the preview
Go deeper on NCT05092802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05092802.